First-line treatment in advanced non-small-cell lung cancer: The emerging role of the histologic subtype

Marcello Tiseo, Marco Bartolotti, Francesco Gelsomino, Andrea Ardizzoni

Research output: Contribution to journalArticlepeer-review


Lung cancer is the leading cause of cancer mortality worldwide. During the past quarter of a century, there have been definite steps forward in understanding the biology of this disease. However, progress in the treatment of advanced non-small-cell lung cancer (NSCLC) has been more elusive and has not been associated with a realistic probability of long-term survival. For this disease, platinum-based chemotherapy is currently the standard treatment. Numerous studies have compared various platinum doublets and have concluded that all such combinations are comparable in their clinical efficacy. Moreover, several trials evaluating different chemotherapy regimens in NSCLC have failed to document a difference based on histology. Recent evidence suggests that histology represents an important variable in the decision making. This review will discuss this new evidence in the first-line treatment of advanced NSCLC, focusing on different possible therapeutic approaches according to histologic subtype.

Original languageEnglish
Pages (from-to)425-435
Number of pages11
JournalExpert Review of Anticancer Therapy
Issue number4
Publication statusPublished - 2009


  • Adenocarcinoma
  • Bevacizumab
  • Cetuximab
  • Non-small-cell lung cancer
  • Pemetrexed
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'First-line treatment in advanced non-small-cell lung cancer: The emerging role of the histologic subtype'. Together they form a unique fingerprint.

Cite this